Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 1059

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 1059
---
. If any term of Series A Preferred Stock set forth herein is invalid, unlawful or incapable of being enforced by reason of any rule of law or public policy, all other terms set forth herein which can be given effect without the invalid, unlawful or unenforceable term will, nevertheless, remain in full force and effect, and no term herein set forth will be deemed dependent upon any other such term unless so expressed herein.

<div align='center'>[Signature Page to Follow]

G-8</div>

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Designations to be duly executed and acknowledged by its undersigned duly authorized officer this __ day of ________, 2024.

| SEMNUR PHARMACEUTICALS, INC. |
| By:                          |
| Name:                        |
| Title:                       |

[ Signature Page to Certificate of Designations]

Annex H

Board of Directors Denali Capital Acquisition Corp. (NASDAQ: DECA) 437 Madison Avenue 27 thFloor New York, NY 10022 Re: Opinion of Value of the Proposed Transaction Among DENALI CAPITAL ACQUISITION CORP. (NASDAQ: DECA). and SEMNUR PHARMACEUTICALS, INC. Dear Denali Board of Directors: We understand that Denali Capital Acquisition Corp., a Cayman Islands corporation and special purpose acquisition company, (NASDAQ: DECA or the “Company”) and Semnur Pharmaceuticals, Inc., (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (NASDAQ: SCLX or “Scilex”), (together referenced as the “Parties”), propose to enter into an Agreement and Plan of Merger (the “Merger Agreement”), and as outlined in the corresponding Letter of Intent dated July 02, 2024, pursuant to which both Parties intend to create a single publicly traded biopharma company to further provide investment into Semnur for the development of a non-opioidproduct, SP-102.Following the consummation of the Merger Agreement which provides for, among other things, the merger (the “Merger” and, together the “Transaction”), the Parties intend to file a registration statement on Form S-4with the Securities and Exchange Commission (the “SEC”), which would include a proxy statement/prospectus, and each party would file other documents regarding the proposed transaction with the SEC. Our understanding of the Parties is summarized as follows

| i. | Semnur Pharmaceuticals,